These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38062852)

  • 1. Exposure of quantum dots in the nervous system: Central nervous system risks and the blood-brain barrier interface.
    Guan S; Tang M
    J Appl Toxicol; 2024 Jul; 44(7):936-952. PubMed ID: 38062852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research advances on potential neurotoxicity of quantum dots.
    Wu T; Zhang T; Chen Y; Tang M
    J Appl Toxicol; 2016 Mar; 36(3):345-51. PubMed ID: 26364743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recapitulation of Structure-Function-Regulation of Blood-Brain Barrier under (Patho)Physiological Conditions.
    Fong H; Zhou B; Feng H; Luo C; Bai B; Zhang J; Wang Y
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanodelivery systems for overcoming limited transportation of therapeutic molecules through the blood-brain barrier.
    Kim KT; Lee HS; Lee JJ; Park EK; Lee BS; Lee JY; Bae JS
    Future Med Chem; 2018 Nov; 10(22):2659-2674. PubMed ID: 30499740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxidative stress-induced neurotoxicity of quantum dots and influencing factors.
    Fang Q; Tang M
    Nanomedicine (Lond); 2024; 19(11):1013-1028. PubMed ID: 38606672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypoxic Stress and Inflammatory Pain Disrupt Blood-Brain Barrier Tight Junctions: Implications for Drug Delivery to the Central Nervous System.
    Lochhead JJ; Ronaldson PT; Davis TP
    AAPS J; 2017 Jul; 19(4):910-920. PubMed ID: 28353217
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential neurotoxicity of nanoparticles.
    Hu YL; Gao JQ
    Int J Pharm; 2010 Jul; 394(1-2):115-21. PubMed ID: 20433914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dysfunction of the Neurovascular Unit by Psychostimulant Drugs.
    Vo TTL; Shin D; Ha E; Seo JH
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbon dots as dual inhibitors of tau and amyloid-beta aggregation for the treatment of Alzheimer's disease.
    Zhang W; Smith N; Zhou Y; McGee CM; Bartoli M; Fu S; Chen J; Domena JB; Joji A; Burr H; Lv G; Cilingir EK; Bedendo S; Claure ML; Tagliaferro A; Eliezer D; Veliz EA; Zhang F; Wang C; Leblanc RM
    Acta Biomater; 2024 Jul; 183():341-355. PubMed ID: 38849023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Obesity-induced blood-brain barrier dysfunction: phenotypes and mechanisms.
    Feng Z; Fang C; Ma Y; Chang J
    J Neuroinflammation; 2024 Apr; 21(1):110. PubMed ID: 38678254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanowired Drug Delivery Across the Blood-Brain Barrier in Central Nervous System Injury and Repair.
    Sharma A; Menon P; Muresanu DF; Ozkizilcik A; Tian ZR; Lafuente JV; Sharma HS
    CNS Neurol Disord Drug Targets; 2016; 15(9):1092-1117. PubMed ID: 27538949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unravelling the Potential of Graphene Quantum Dots in Biomedicine and Neuroscience.
    Perini G; Palmieri V; Ciasca G; De Spirito M; Papi M
    Int J Mol Sci; 2020 May; 21(10):. PubMed ID: 32466154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors influencing the blood-brain barrier permeability.
    Zhao Y; Gan L; Ren L; Lin Y; Ma C; Lin X
    Brain Res; 2022 Aug; 1788():147937. PubMed ID: 35568085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Carbon Dots: A Future Blood-Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier.
    Zhang W; Sigdel G; Mintz KJ; Seven ES; Zhou Y; Wang C; Leblanc RM
    Int J Nanomedicine; 2021; 16():5003-5016. PubMed ID: 34326638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transporters at CNS barrier sites: obstacles or opportunities for drug delivery?
    Sanchez-Covarrubias L; Slosky LM; Thompson BJ; Davis TP; Ronaldson PT
    Curr Pharm Des; 2014; 20(10):1422-49. PubMed ID: 23789948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNAs in central nervous system diseases: A prospective role in regulating blood-brain barrier integrity.
    Ma F; Zhang X; Yin KJ
    Exp Neurol; 2020 Jan; 323():113094. PubMed ID: 31676317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent expansions of novel strategies towards the drug targeting into the brain.
    Alexander A; Agrawal M; Uddin A; Siddique S; Shehata AM; Shaker MA; Ata Ur Rahman S; Abdul MIM; Shaker MA
    Int J Nanomedicine; 2019; 14():5895-5909. PubMed ID: 31440051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In-vitro blood-brain barrier models for drug screening and permeation studies: an overview.
    Bagchi S; Chhibber T; Lahooti B; Verma A; Borse V; Jayant RD
    Drug Des Devel Ther; 2019; 13():3591-3605. PubMed ID: 31695329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A method to predict different mechanisms for blood-brain barrier permeability of CNS activity compounds in Chinese herbs using support vector machine.
    Jiang L; Chen J; He Y; Zhang Y; Li G
    J Bioinform Comput Biol; 2016 Feb; 14(1):1650005. PubMed ID: 26632324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of micro- and nanoplastics on the central nervous system: A new threat to humanity?
    Zheng Y; Xu S; Liu J; Liu Z
    Toxicology; 2024 May; 504():153799. PubMed ID: 38608860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.